網膜色素変性症(網膜炎):パイプラインインサイト2018

◆英語タイトル:Retinitis Pigmentosa (Retinitis) - Pipeline Insight, 2018
◆商品コード:DELV202084
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年1月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:世界
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD1,250 ⇒換算¥138,750見積依頼/購入/質問フォーム
Site Price(同一事業所内共有可)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Enterprise Price(複数事業所内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、網膜色素変性症(網膜炎)の治療薬開発パイプラインについて調査・分析し、網膜色素変性症(網膜炎)の概要、網膜色素変性症(網膜炎)の臨床試験段階の治療薬分析、主要な製薬メーカー動向などを含め、以下の構成でお届け致します。
・網膜色素変性症(網膜炎)の概要
・網膜色素変性症(網膜炎)の治療薬開発パイプライン
・網膜色素変性症(網膜炎)の比較分析
・網膜色素変性症(網膜炎)の治験段階の製品(医薬品)
・網膜色素変性症(網膜炎)の前臨床&創薬段階の製品
・主要企業動向
・治療評価(分析)
【レポートの概要】

“Retinitis Pigmentosa (Retinitis) – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Retinitis Pigmentosa (Retinitis) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Retinitis Pigmentosa (Retinitis)
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Retinitis Pigmentosa (Retinitis)
The report assesses the active Retinitis Pigmentosa (Retinitis) pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Retinitis Pigmentosa (Retinitis)
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Retinitis Pigmentosa (Retinitis)
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Retinitis Pigmentosa (Retinitis)
• The report also covers the dormant and discontinued pipeline projects related to the Retinitis Pigmentosa (Retinitis)

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Retinitis Pigmentosa (Retinitis) to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Retinitis Pigmentosa (Retinitis) therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

【レポートの目次】

1. Report Introduction
2. Retinitis Pigmentosa (Retinitis) Overview
3. Pipeline Therapeutics
• An Overview of Pipeline Products for Retinitis Pigmentosa (Retinitis)
4. Comparative Analysis
5. Products in Clinical Stage
5.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
6.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
7. Therapeutic Assessment
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
8. Inactive Products
8.1 Drug Name : Company Name
• Product Description
• Research and Development
• Product Development Activities
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight

Table 1: Total Products for Retinitis Pigmentosa (Retinitis)
Table 2: Products in Clinical Stage
Table 3: Products in Non-clinical Stage
Table 4: Assessment by Route of Administration
Table 5: Assessment by Stage and Route of Administration
Table 6: Assessment by Molecule Type
Table 7: Assessment by Stage and Molecule Type
Table 8: Inactive Products


Figure 1: Total Products for Retinitis Pigmentosa (Retinitis)
Figure 2: Products in Clinical Stage
Figure 3: Products in Non-clinical Stage
Figure 4: Assessment by Route of Administration
Figure 5: Assessment by Stage and Route of Administration
Figure 6: Assessment by Molecule Type
Figure 7: Assessment by Stage and Molecule Type
Figure 8: Inactive Products


【掲載企業】

Acucela Inc
Allergan Plc
Amarantus Bioscience Holdings Inc
Amgen Inc
Applied Genetic Technologies Corp
Asklepios BioPharmaceutical Inc
Astellas Pharma Inc
Caladrius Biosciences Inc
Dompe Farmaceutici SpA
GenSight Biologics SA
Grupo Ferrer Internacional SA
ID Pharma Co Ltd
& list continues…

【レポートのキーワード】

網膜色素変性症(網膜炎)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[網膜色素変性症(網膜炎):パイプラインインサイト2018]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆